Plain-English translation of NCT06428188 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach using CAR-T cells—your own immune cells that have been modified in the laboratory to target and reduce the cells driving your autoimmune disease. Researchers want to see whether this treatment is safe and whether it can help people whose autoimmune conditions (like lupus or Sjögren's syndrome) have not responded well to standard medications. The goal is to understand how well the medication works and whether it causes serious side effects.
Many people with severe autoimmune diseases continue to suffer even after trying multiple standard treatments. This new treatment offers a potential option for those whose diseases have become resistant to conventional medications by taking a different approach—using your body's own immune system in a new way.
You likely qualify if…
You likely don't qualify if…
You will receive two chemotherapy medications (fludarabine and cyclophosphamide) given intravenously over a few days to prepare your body. Then you will receive the specially modified immune cells intravenously. Depending on how you respond and how well you tolerate the treatment, you may be eligible to receive up to 3 additional doses of the cells. Throughout the study, researchers will monitor your health closely for safety concerns and will track how your autoimmune disease responds to the treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China